Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH-Reference-Cited by-同舟云学术

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Published:2020-01 Issue:1 Volume:10 Page:1-12
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Benza Raymond L.¹,Corris Paul A.²,Ghofrani Hossein‐Ardeschir³⁴,Kanwar Manreet⁵,McLaughlin Vallerie V.⁶,Raina Amresh⁵,Simonneau Gérald⁷

Affiliation:

1. Division of Cardiovascular MedicineOhio State University Wexner Medical CenterColumbusOHUSA

2. Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUK

3. University of Giessen and Marburg Lung CentreGiessenGermany

4. Department of MedicineImperial College LondonLondonUK

5. Cardiovascular InstituteAllegheny General HospitalPittsburghPAUSA

6. University of Michigan Health SystemAnn ArborMIUSA

7. Assistance Publique–Hôpitaux de ParisService de PneumologieHôpital BicêtreUniversité Paris‐SudLaboratoire d’Excellence en Recherche sur le Médicament et Innovation ThérapeutiqueINSERM Unité 999Le Kremlin–BicêtreFrance

Funder

Bayer

Bayer AG

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894019837849

Reference72 articles.

1. Chronic thromboembolic pulmonary hypertension: an updated review;Lang IM;Curr Opin Cardiol,2008

2. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension;Peacock A;Proc Am Thorac Soc,2006

3. Updated clinical classification of pulmonary hypertension;Simonneau G;J Am Coll Cardiol,2009

4. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);Galiè N;Eur Respir J,2015

5. Treatment of pulmonary hypertension;Hoeper MM;Lancet Respir Med,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health;The Journal of Sexual Medicine;2023-12-26

2. Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases;Frontiers in Pharmacology;2023-12-20

3. Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis;Frontiers in Pharmacology;2023-01-26

4. Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective;Vascular Health and Risk Management;2022-10

5. Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography;Journal of Clinical Medicine;2022-07-12